Advertisement
YOU ARE HERE: LAT HomeCollectionsUpjohn
IN THE NEWS

Upjohn

FEATURED ARTICLES
BUSINESS
January 8, 1987 | HENRY RIVERO, Times Staff Writer
In its first major move since acquiring control of Applied Circuit Technology, Locke-Sweatman Investments of Austin, Tex., said it has appointed a new president to head up the company's generic pharmaceuticals subsidiary, Gardena-based Whiteworth International Inc. The Texas partnership, which bought 33% of Anaheim-based ACT last month, has named Dale Garlow, 45, a former Upjohn Co. executive, to fill the seat vacated by Walter R. Menetrey.
ARTICLES BY DATE
CALIFORNIA | LOCAL
December 6, 2006 | From Times Staff and Wire Reports
Ray T. "Ted" Parfet Jr., 84, the last member of the Upjohn family to lead the pharmaceutical firm, died Nov. 27 at a hospital in Kalamazoo, Mich., of pulmonary and cardiovascular complications. Parfet was married for 61 years to Martha Gilmore Parfet, a granddaughter of W.E. Upjohn, the company's founder. As chairman and chief executive of the company from 1969 until his retirement in 1987, Parfet led the company through a period of international expansion.
Advertisement
BUSINESS
December 21, 1999 | Associated Press
The planned merger of Monsanto Co. and Pharmacia & Upjohn Inc. rattled investors, as shareholders thought both U.S. pharmaceutical companies could have made a better deal. But analysts said the companies are making the right move to sustain their long-term growth. Monsanto's products include the blockbuster arthritis treatment Celebrex, farm chemicals and genetically engineered seeds. Pharmacia's major products are the contraceptive Depo-Provera and the over-the-counter hair-growth gel Rogaine.
NEWS
August 10, 1987 | JOHN SANSING, Sansing is executive editor of The Washingtonian magazine, for which this article was first written. and
At 7:15 on a cold Monday morning in March, a long line of well-dressed men and women snaked around a subterranean hallway of the Food and Drug Administration building in Rockville, Md. By 8:30 a.m., when the meeting of the Dermatologic Drugs Advisory Committee was to convene, the more than 100 seats in Conference Room C had been claimed, a press section was filled, seven TV camera crews had staked claim to adequate sight lines and dozens of people were trying to get in.
BUSINESS
November 21, 1996 | Times Staff and Wire Reports
Pharmacia & Upjohn Inc., a Swedish-American drug maker, said it will cooperate with San Diego-based Prizm Pharmaceuticals in developing the ophthalmology drug Pantarin. The protein-based drug is mainly used to treat post-cataract opacification, a condition that appears in 30% to 50% of the 4 million patients annually who have lens-replacement operations after cataract surgery. It works by seeking out and destroying proliferating cells.
BUSINESS
February 23, 1990 | United Press International
The board of directors of the Upjohn Co. has approved formation of Upjohn Laboratories, a new corporate entity that combines the company's pharmaceutical research and medical functions. The board has also elected Jerry R. Mitchell, formerly vice president for pharmaceutical research, to be senior vice president and president of Upjohn Laboratories.
BUSINESS
January 21, 1997 | Times Staff and Wire Reports
John Zabriskie, president and chief executive of Swedish-U.S. pharmaceutical giant Pharmacia & Upjohn Inc., unexpectedly announced his resignation. The move comes amid disappointing profit for the maker of Rogaine hair restorer, Kaopectate for diarrhea and Halcion tranquilizers. The company, created in 1995 through the merger of Upjohn Co. & Sweden's Pharmacia, has also had difficulty consolidating its two halves.
BUSINESS
July 17, 1990 | United Press International
Upjohn Co. said today that its second-quarter earnings jumped 21% from last year, while sales for the period rose 11%. The pharmaceutical giant said it earned $114.1 million, or 62 cents a share, from continuing operations in the second quarter vs. $94.6 million, or 51 cents a share, in the same quarter in 1989.
BUSINESS
October 16, 1985
Two leading drug companies, Upjohn Co. and Pfizer Inc., reported double-digit profit increases for the third quarter, while a third drug company, American Cyanamid, reported a 32% profit decline. Upjohn, a Kalamazoo, Mich.-based pharmaceutical maker, reported that its net earnings rose 75% to $46.9 million on sales of $474.7 million in the three months ended Sept. 30. In the same period last year, Upjohn reported a profit of $26.8 million on sales of $435.3 million.
BUSINESS
December 20, 1999 | GEORGE STEIN and BRETT CHASE, BLOOMBERG NEWS
Monsanto Co. and rival drug maker Pharmacia & Upjohn Inc. on Sunday agreed to merge in a $26.5-billion stock transaction and sell off part of the agriculture business that helped drag Monsanto's share price down 12% this year. Monsanto stockholders will exchange each of their shares for a share of the combined company in the transaction, described as a merger of equals without a premium for shareholders. Pharmacia shareholders will receive 1.19 shares for each of their shares, a 1.
BUSINESS
December 18, 1999 | NOELLE KNOX, ASSOCIATED PRESS
Monsanto Co., continuing its search for a buyer, is talking to Pharmacia & Upjohn Inc. about a merger that would create a drug company with products ranging from arthritis pain relievers to smoking-cessation gum, a person familiar with the situation said Friday. The two companies are still far apart on key issues, said the person, who spoke on condition of anonymity.
BUSINESS
October 14, 1997 | From Associated Press
Pharmacia & Upjohn Inc. said Monday that it is moving its headquarters from London to the East Coast and shifting or cutting 600 jobs at its Kalamazoo, Mich., facility. Relocating the home office of the pharmaceutical giant will help it respond more quickly to market changes and keep it "tightly linked to the marketplace," said Fred Hassan, who became chief executive in May.
BUSINESS
July 9, 1997 | DENISE GELLENE, TIMES STAFF WRITER
Pharmacia & Upjohn began airing commercials Tuesday for Depo-Provera, becoming the first company to advertise a female contraceptive on television. The two-minute spots premiered on three cable TV networks and on local stations in Nashville; Kansas City, Mo.; Seattle; and Columbus, Ohio. The campaign is considered a test and will last three weeks. Broadcasters have been skittish about birth control ads, and Pharmacia & Upjohn encountered resistance in getting its commercials on the air.
BUSINESS
January 21, 1997 | Times Staff and Wire Reports
John Zabriskie, president and chief executive of Swedish-U.S. pharmaceutical giant Pharmacia & Upjohn Inc., unexpectedly announced his resignation. The move comes amid disappointing profit for the maker of Rogaine hair restorer, Kaopectate for diarrhea and Halcion tranquilizers. The company, created in 1995 through the merger of Upjohn Co. & Sweden's Pharmacia, has also had difficulty consolidating its two halves.
BUSINESS
November 21, 1996 | Times Staff and Wire Reports
Pharmacia & Upjohn Inc., a Swedish-American drug maker, said it will cooperate with San Diego-based Prizm Pharmaceuticals in developing the ophthalmology drug Pantarin. The protein-based drug is mainly used to treat post-cataract opacification, a condition that appears in 30% to 50% of the 4 million patients annually who have lens-replacement operations after cataract surgery. It works by seeking out and destroying proliferating cells.
BUSINESS
December 21, 1999 | Associated Press
The planned merger of Monsanto Co. and Pharmacia & Upjohn Inc. rattled investors, as shareholders thought both U.S. pharmaceutical companies could have made a better deal. But analysts said the companies are making the right move to sustain their long-term growth. Monsanto's products include the blockbuster arthritis treatment Celebrex, farm chemicals and genetically engineered seeds. Pharmacia's major products are the contraceptive Depo-Provera and the over-the-counter hair-growth gel Rogaine.
BUSINESS
August 8, 1985
The Kalamazoo, Mich.-based drug company said it is investing $23 million in a manufacturing facility for Minoxidil, a drug that it believes could cure male pattern baldness--the type of hair loss that many men experience with advancing age--and patchy baldness--a massive loss of hair all over the body. The drug, which Upjohn first developed as a treatment for high blood pressure, is in the final stages of testing on human volunteers.
BUSINESS
April 19, 1996 | DENISE GELLENE, TIMES STAFF WRITER
Pharmacia & Upjohn is launching TV spots for its over-the-counter baldness treatment this weekend amid a high-stakes effort to fend off competitors to Rogaine. The spots, aimed at men and women, aren't hair-raising in themselves. In one commercial, a balding man uses Rogaine at the urging of his wife and sees modest results four months later. "See, there's room for growth in every relationship," says his wife.
BUSINESS
August 22, 1995 | From Associated Press
It sounds like simple economics. As drug companies continue their merger frenzy, there will be less competition, resulting in less innovation and higher prices for consumers, right? Not necessarily, say industry watchers, who point out that other factors, such as the growth of health maintenance organizations and the public's demand for more non-prescription medicines, continue to push prices downward. Sunday's $13-billion proposed linkup of Sweden's Pharmacia and the United States' Upjohn Co.
Los Angeles Times Articles
|